Author: Ravi Shankar

MONTREAL, Oct. 21, 2026 (GLOBE NEWSWIRE) — Gildan Activewear Inc. (GIL; TSX and NYSE) will report its 2026 third quarter financial and operating results on Thursday, November 5, 2026. A press release will be issued before markets open, and a conference call is scheduled on that same day at 8:30 AM ET to discuss the Company’s results.

Glenn J. Chamandy, Gildan’s President and Chief Executive Officer, Luca Barile, Executive Vice President, Chief Financial Officer, Chuck Ward, Executive Vice President, Chief Commercial Officer and Jessy Hayem, Senior Vice President, Head of Investor Relations and Global Communications, will participate in this call intended for financial analysts and institutional investors.

The conference call can be accessed by dialing (800) 715-9871 (Canada & U.S.) or (646) 307-1963 (international) and entering passcode 9609115#. A replay will be available for 7 days starting at 12:30 PM EST by dialing (800) 770-2030 (Canada & U.S.) or (609) 800-9909 (international) and entering the same passcode. A live audio webcast of the conference call, as well as the replay, will be available at the following link: Gildan Q3 2026 audio webcast.

About Gildan
Gildan is a leading manufacturer of everyday basic apparel. The Company’s product offering includes activewear, underwear, socks, and intimates sold to a broad range of customers, including wholesale distributors, screenprinters, embellishers, retailers or e-commerce platforms, as well as global lifestyle brand companies and directly to consumers. Gildan markets its products in North America, Europe, Asia Pacific, and Latin America, under a diversified portfolio of Company-owned brands including Gildan®, Hanes®, Comfort Colors®, American Apparel®, ALLPRO™, GOLDTOE®, Peds®, Bali®, Playtex®, Maidenform®, Bonds®, as well as Champion™ which is under an exclusive licensing agreement for the printwear channel in the U.S. and Canada and Polo Ralph Lauren® also under a licensing agreement.

Gildan owns and operates vertically integrated, large-scale manufacturing facilities which are primarily located in Central America, the Caribbean, North America, and Asia. Gildan integrates industry-leading labour, environmental, and governance practices into its operations and supply chain under a sustainability program that is aligned with its long-term business strategy. More information about Gildan and its sustainability commitments and initiatives can be found at www.gildancorp.com

Investor inquiries: Jessy Hayem, CFA Senior Vice-President, Head of Investor Relations and Global Communications (514) 744-8511 investors@gildan.com

Media inquiries: Jonathan Binder Director, Corporate Communications (336) 519-6330 communications@gildan.com

HOUSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) — Westlake Chemical Partners (NYSE: WLKP) will release its third quarter 2026 earnings prior to the market opening on Wednesday, November 4, 2026. The company will host a conference call at 1:00 p.m. Eastern Time (12:00 p.m. Central Time) on the same day to discuss the earnings release.

To access the conference by phone, it is necessary to pre-register at https://register-conf.media-server.com/register/BI3f3870a5aac84874bbbc7d18dbd188bc. Once registered, you will receive a phone number and unique PIN number. When you dial in, you will input the PIN number to be placed into the call.

The conference call and replay will be available via webcast at https://edge.media-server.com/mmc/p/so37ydoy and the earnings release can be obtained via the company’s Web page at https://investors.wlkpartners.com.

About Westlake Chemical Partners:

Westlake Chemical Partners is a limited partnership formed by Westlake Corporation to operate, acquire and develop ethylene production facilities and other qualified assets. Headquartered in Houston, the Partnership owns an 22.8% interest in Westlake Chemical OpCo LP. Westlake Chemical OpCo LP’s assets consist of three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana and an ethylene pipeline. For more information about Westlake Chemical Partners LP, please visit http://www.wlkpartners.com.

For Further Information Contact:
Media Relations – L. Ben Ederington – 713.585.2900
Investor Relations – Jonathan Baksht – 713.585.2900

Seed orders for the FY 2027 season up more than 100% Ytd, targeting 50%+ Yoy revenue growth for FY 2027

BEIJING, Oct. 21, 2026 (GLOBE NEWSWIRE) — Origin Agritech Limited (NASDAQ: SEED) (“Origin” or the “Company”), a leading Chinese agricultural technology company, today issued a letter to shareholders from Chief Executive Officer Weibin Yan as the Company enters fiscal year 2027. The full text follows.

Dear Fellow Shareholders,

Two years ago, in August 2024, I returned to Origin Agritech as Chief Executive Officer with a clear objective: to strengthen our position in China’s corn seed industry and build a foundation for sustainable growth.. We closed fiscal 2026 on September 30 with the first phase of our strategic plan complete. Early indicators are encouraging: customer advance payments and seed preorders for spring planting are up more than 100% year-over-year to date. I would like to share the progress we have made, the opportunities ahead, and how we intend to build on this momentum.

Building the Foundation for Growth: The Restructuring Stage

When I rejoined Origin in August 2024, we established a three-stage development plan. Fiscal 2025 and 2026 comprised the Restructuring Stage, during which we made substantial progress. We strengthened our leadership team and expanded sales and marketing across China’s major corn seed regions, re-entering Northeast China last year and launching operations in Guizhou in June this year. We launched four new corn varieties in August 2025, secured exclusive nationwide commercialization rights to Zhongdan 6202 one year later, and began introducing Bangzhongbang 889 for FY 2027.

We upgraded R&D stations in Beijing and Sanya, opened new stations in Zhengzhou and Guizhou. We obtained gene-editing trait authorizations, partnered with China Agricultural University and the Beijing Academy of Agricultural and Forestry Sciences to advance biotechnology commercialization, obtained Beijing Origin’s seed production and operation license, and implemented an AI-assisted information management system. We also completed a sale-and-leaseback of our Xinjiang seed production subsidiary, unlocking capital while retaining operational access, strengthening liquidity without shareholder dilution.

What to expect in FY 2027: The Strong Growth Stage Begins

Fiscal 2027 through fiscal 2029 marks our Strong Growth Stage. The new fiscal 2027 season started very well with our new seed varieties have receiving encouraging market responses across our main business regions. Advance payments are up more than 100% year-over-year in this early season. Building on this momentum, we expect our operating cash flow from the seed business to more than double year over year in FY 2027.

Three engines are driving that growth: our variety portfolio, led by Zhongdan 6202 and Bangzhongbang 889, with new varieties supporting central China; our regional expansion, including full seasons in Northeast China and Guizhou; and most importantly, our technology platform is greatly improving our R&D efficiency, and the planned Origin Agri-tech Agent will greatly accelerate our engagement with the farmers to improve farmer productivity, deepen and broaden our client relationships.

Looking ahead, we are pursuing organic growth and evaluating M&A opportunities in China and Southeast Asia, supported by our international capital platform. For FY 2028 and FY 2029, we target at least 50% year-over-year organic business growth as our new varieties expand across the Huanghuai-Hai belt and China’s Northeast, Northwest, and Southwest regions.

A personal note

I returned to Origin because I believe China’s corn seed market offers significant opportunities for companies with strong genetics, effective distribution, and innovative technology. With more than 200,000 germplasm accessions, authorized gene-edited traits, a growing variety portfolio, and an expanded sales network,strong engagement with the leading experts in the industry, Origin is building the capabilities to capture these opportunities. Our goal is to become one of  China’s leading corn seed companies within five years, and the more than 100% year-over-year increase in advance payments to date is an encouraging early indicator of customer demand. My own capital is invested alongside yours.

Thanks for your investment and attention, I look forward to speaking with you on our next call.

Sincerely,
Weibin Yan
Chief Executive Officer
Origin Agritech Limited

About Origin Agritech Limited

Origin Agritech Limited, founded in 1997 and headquartered at the Origin R&D Center in Songzhuang, Tongzhou, Beijing, is a leading Chinese agricultural technology company. In crop seed biotechnology, Origin Agritech’s phytase corn was the first transgenic corn to receive a Biosafety Certificate from China’s Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and Bt (pest resistance) traits. For further information, please visit the Company’s website at https://originagritech.com. The Company also maintains an X account to update investors on Company and industry developments, available at https://x.com/origin_agritech.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s expectations for advance payments and seed sales in fiscal 2027, the launch and market acceptance of Zhongdan 6202, Bangzhongbang 889, and other varieties, the launch, timing, and expected benefits of the Company’s Farming AI Agent, and AI-asisted information management system, the Company’s three-stage strategic plan and the targets for each stage, the use of capital from the sale and leaseback of the Xinjiang subsidiary and its effect on the Company’s results and liquidity, regulatory and commercial milestones for new and biotechnology-derived varieties, potential acquisitions and international expansion, and the Company’s strategic goals. Words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “will,” “would,” “target,” and similar expressions identify forward-looking statements. These statements involve known and unknown risks and uncertainties, including the risk that advance payments do not convert into seed sales at the level or timing expected, delays in or failure to achieve regulatory and commercial milestones, grower adoption of the Company’s varieties, seed production yields and weather conditions, competitive variety introductions, pricing pressure in the Chinese seed market, regulatory and agricultural policy developments in China, currency fluctuation, risks associated with international operations and licensing approvals, and the Company’s ability to fund and execute the plans described above, which may cause actual results to differ materially from those expressed or implied. Forward-looking statements are not guarantees of future performance. Origin Agritech undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by securities and other applicable laws.

For more information, please contact:

Origin Agritech Limited Contact:

Kate Lang (Mandarin/English)
Director of Investor Relations
Phone: +86 186-1839-3368
Email: bing.lang@originseed.com.cn

Investor Relations Contact:

Matthew Abenante, IRC
President
Strategic Investor Relations LLC
Tel: 347-947-2093
Email: matthew@strategic-ir.com

New standalone product platform under development would position Silynxcom to address a significantly expanded defense market beyond its traditional tactical communication accessories business

AI-powered acoustic drone detection is being designed to give individual soldiers real-time threat warnings, which would be capable to connect through an autonomous mesh network where multiple devices can share alerts across an entire platoon, without requiring integration with existing tactical communication systems.

NETANYA, Israel, Oct. 21, 2026 (GLOBE NEWSWIRE) — Silynxcom Ltd. (NYSE American: SYNX) (“Silynxcom” or the “Company”), a developer of advanced soldier-worn tactical communication solutions, today announced its strategic entry into the counter-uncrewed aircraft systems (“C-UAS”) market through the development of a new wearable drone detection and early-warning platform powered by artificial intelligence (“AI”). The Company aims to address one of the most persistent challenges in modern warfare: protecting individual soldiers from drone threats while on the move.

The wearable detection device, currently at prototype stage, is designed to detect drone acoustic signatures in real time. Because the system relies on acoustic signatures rather than detecting drone radio transmissions, it is designed to identify threats that conventional radio frequency-based detectors may miss, including fiber-optic guided drones. These drones emit no radio signal, but every drone makes noise.

According to a Fortune Business Insights anti-drone market study, the market for C-UAS detection and interdiction technologies is projected to grow from $3.88 billion in 2026 to $16.45 billion by 2034, a compound annual growth rate of 19.79%.

Rather than an enhancement to existing tactical communication equipment, Silynxcom is developping this new platform as a standalone product. It is designed to operate without integration into tactical radio systems, while retaining the option to connect with existing tactical communication equipment where customers require it.

This architecture is intended to enable Silynxcom to address a broader range of military customers, operational requirements and defense procurement programs, creating the potential for a new business line and an additional growth engine alongside the Company’s existing business of ruggedized tactical communication headset devices.

From Individual Soldier Protection to Networked Unit Defense

The wearable detection device’s on-device AI analyzes potential drone signatures and the wearer receives an alert. The acoustic detection capability builds on Silynxcom’s combat-proven personnel headset, which already amplifies drone sounds for soldiers in the field while protecting their hearing from the continuous and sudden noise of the battlefield.

A mesh networking capability is under development and is being designed to allow multiple wearable devices to connect and form coordinated protection groups, such that an alert generated by one device could be shared across connected platoon members, enabling collective situational awareness and coordinated early warning without dependence on existing infrastructure.

The modular approach is intended to allow customers to deploy the technology for individual soldier protection or scale it across military units, according to their operational needs.

Dedicated and Experienced C-UAS Development Team

The Company is establishing a dedicated team to lead its counter-drone activities. The team includes recently recruited professionals with years of experience in drone technologies, including at leading drone manufacturers in Israel. The team will draw on Silynxcom’s experience in tactical acoustics, soldier-worn electronics and ruggedized military equipment to accelerate development of the new business.

Nir Klein, Chief Executive Officer of Silynxcom, commented: “From Ukraine to the Middle East, modern warfare has brought the drone threat down to the individual soldier. Troops need warning that moves with them as they disperse and operate beyond defended positions. Fixed-site defenses are important, but they are only one part of the protection soldiers need. This initiative represents more than the development of a new product. It marks our strategic entry into an entirely new defense market.

By designing a wearable detection device combined with networked group protection, we aim to help address the protection gap at the individual-soldier level and turn one soldier’s drone warning into shared awareness across a connected platoon. We believe this can establish a new platform for long-term growth.”

About Silynxcom Ltd.

We develop, manufacture, and sell ruggedized tactical protective and communication headset devices as well as other communication accessories, all of which have been field-tested and combat proven. Our in-ear headset devices, or In-Ear Headsets, are used in combat, riot control, demonstrations, weapons training courses, and factory floors. Our In-Ear Headsets seamlessly integrate with third party manufacturers of professional-grade ruggedized radios that are used by soldiers, homeland security personnel, police officers and civilian users worldwide. Our In-Ear Headsets provide high levels of sound protection, fit tightly into the protective gear to enable users to speak and hear clearly and precisely while they are protected from the hazardous sounds of combat, riots, dangerous situations and machine equipment in factories. Our sleek, lightweight, In-Ear Headsets allow wearing with any helmet type to reduce head injuries, allow wearing any earwear and in any weather condition. Our technology provides active sound protection to eliminate unsafe sounds, while maintaining ambient environmental awareness, giving our customers 360° situational awareness. Our new upgraded “drone detection” headset, sound leak test and prerecorded messages technologies provide additional, unique, features and protection level to operators in modern combat arenas. The Company is developing an AI-powered wearable drone-detection and early-warning platform intended for military and security applications.

For additional information about the Company please visit: https://silynxcom.com

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. For example, the Company uses forward-looking statements when it discusses: the Company’s entry into the C-UAS market; strategically targeting the counter-drone defense market; the development, anticipated capabilities, attributes , and potential market acceptance of the wearable drone-detection and mesh-networking platform; the intention of the Company to address a broader range of military customers, operational requirements and defense procurement programs, creating the potential for a new business line and an additional growth engine alongside the Company’s existing business; the anticipated benefits of the platform; and the growth and opportunities of the C-UAS market. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 30, 2026, and other documents filed with or furnished to the SEC, which are available on the SEC’s website, www.sec.gov. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Capital Markets and Investor Relations Contact

ir@silynxcom.com

Proposed collaboration covers scientific exchange, specialist training and real-world evidence, alongside assessment of clinical trial opportunities and a potential regional presence for NeOnc in Abu Dhabi

Two children in Abu Dhabi are receiving investigational NEO100 through NeOnc’s Compassionate Care program, with a third expected this week

CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 21, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that it has signed a Memorandum of Understanding (MoU) with the Department of Health – Abu Dhabi (DoH) to cooperate on the development of research and clinical capability in oncology and central nervous system therapeutics in the Emirate of Abu Dhabi. The MoU was signed on the sidelines of the Abu Dhabi Future Health Summit (ADFHS) 2026.

Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc Technologies Holdings, Inc., said: “For families facing brain cancer, access to investigational treatments and clinical research opportunities matters deeply. This proposed collaboration creates a framework to bring NeOnc’s development expertise together with Abu Dhabi’s clinical capabilities, with the goal of advancing research and expanding opportunities for patients closer to home. We are grateful to the Department of Health – Abu Dhabi for its commitment to addressing the needs of patients with complex and rare CNS cancers, including children.”

H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi (DoH), said: “For patients and families facing complex CNS cancers, every advance in research offers hope for more effective care and better quality of life. Our proposed collaboration with NeOnc connects international expertise with Abu Dhabi’s clinical capabilities to strengthen the evidence and skills needed to evaluate new approaches responsibly. By developing specialist knowledge and a deeper understanding of these critical conditions, we aim to support care that responds more closely to each patient’s needs, reflecting our commitment to bringing scientific advances closer to our community and beyond.”

The MoU builds on NeOnc’s existing activity in the Emirate, where DoH is the government entity responsible for regulating the health sector. In June 2026, DoH granted Investigational New Drug (IND) status for NEO100, covering the Company’s NEO100-01, NEO100-02 and NEO100-03 protocols across Phase 1, Phase 1b and Phase 2 studies in adults with progressive or recurrent Grade III or IV gliomas, together with pediatric studies authorized for Phase 1 and Phase 1b pending further protocol review. That authorization followed DoH’s IND clearance for NEO212, also announced in June 2026. The DoH clearances apply to the conduct of clinical research and do not constitute marketing authorization, and NeOnc must satisfy additional conditions, including separate DoH Institutional Review Board approval, before patient enrollment in the UAE. Two children in Abu Dhabi are currently receiving investigational NEO100 through NeOnc’s Compassionate Care program. A third child is expected to be onboarded from India this week. Building on that experience and on the Company’s existing DoH clearances, NeOnc is working to open a Phase 1 study of NEO100 in the Emirate.

Under the MoU, the parties will exchange scientific and clinical knowledge and expertise in CNS oncology and in the development and translation of therapeutics for rare, pediatric and high-unmet-need conditions; exchange expertise on clinical development methodologies, including trial design, endpoint selection and response assessment criteria, in support of strengthening clinical development capability in the Emirate; and cooperate on the generation and exchange of real-world evidence and clinical insights relating to CNS tumors in Abu Dhabi, including epidemiological and outcomes data, in accordance with applicable data protection legislation and subject to the required approvals.

The parties will also collaborate on training, capacity-building and professional development initiatives for investigators, clinical research coordinators and allied healthcare professionals, including in clinical trial conduct, neuro-oncology imaging assessment methodologies and molecular diagnostics relevant to CNS tumors, and on the development of Abu Dhabi’s life sciences ecosystem.

The MoU further provides for cooperation on the advancement of clinical research in CNS oncology, including studies of NeOnc’s investigational programs, subject to a separate agreement between the parties and to all applicable regulatory requirements and approvals. Subject to a separate agreement and to all applicable laws, regulations and approvals, the parties will also explore the potential establishment of a regional presence and manufacturing, supply or distribution activities by NeOnc in the Emirate, and the positioning of Abu Dhabi as a potential regional platform for NeOnc’s future development activities. These potential activities remain subject to further assessment, applicable approvals and any necessary definitive agreements.

The MoU is not a binding contract on either party. It takes effect upon signature by representatives of both parties and remains in effect for two years, unless either party gives at least three months’ notice of its wish to terminate. The MoU does not restrict either party from entering into similar arrangements with other institutions.

About the Department of Health – Abu Dhabi (DoH)

The Department of Health – Abu Dhabi is the regulator of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritizes health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programs in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH’s unwavering commitment to predicting, preventing and personalizing healthcare for every individual.

For further information on DoH, visit https://www.doh.gov.ae/ and follow on X, Instagram, Facebook, LinkedIn and YouTube.

About NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers. Its investigational programs include intranasal NEO100 and oral NEO212. NEO212 has completed Phase 1 dose escalation and is advancing toward Phase 2 development. NeOnc exclusively licenses a worldwide portfolio of issued patents and pending applications from the University of Southern California related to NEO100, NEO212 and other drug candidates and delivery approaches. For more information, visit https://neonc.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the Company’s proposed collaboration with the Department of Health – Abu Dhabi, the Company’s clinical development activities in the United Arab Emirates, and the potential establishment of a regional presence in the Emirate. These statements reflect current expectations and involve risks and uncertainties. The Memorandum of Understanding is not binding and may not result in any definitive agreement; activities contemplated by the parties remain subject to separate agreement and to applicable regulatory, institutional and other approvals; future studies may not demonstrate safety or efficacy; and no regulatory pathway or marketing approval is assured. Actual results may differ materially. Readers should consider the risk factors described in the Company’s most recent filings with the Securities and Exchange Commission. These statements speak only as of the date of this release.

The Company undertakes no obligation to update forward-looking statements except as required by law.

“NEO100” and “NEO212” are registered trademarks of NeOnc Technologies Holdings, Inc.

Contacts

DoH Media Contact: Mariam Al Marzooqi msalmarzooqi@doh.gov.ae +971 50 536 6660

NeOnc Company Contact: info@neonc.com NeOnc Investor Contact: Jon Nugent Jon Nugent Communications jon@jonnugent.com 205-566-3026

This press release was published by a CLEAR® Verified individual.

Millions of left-behind 401(k)s may face risks as transfers into Automatic Rollover IRAs snowball

NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) — Workers who leave a job with less than $7,000 in their 401(k) may have their savings moved into an account they never chose. New research from PensionBee, a leading retirement savings provider, shows most of these accounts start losing value right away.

The new white paper, “How Automatic Rollover IRAs Can Wear Down Retirement Savings,” reveals that 68% of Automatic Rollover IRAs lose value after one year. Of accounts still there after eight years, four in ten (39%) are worth less than when they arrived.

Automatic Rollover IRAs, also called Safe Harbor IRAs, exist to protect small 401(k) balances that workers leave behind when they change jobs. If a balance is between $1,000 and $7,000, a former employer can move it out of the company 401(k) plan and into an Automatic Rollover IRA without the worker’s consent.  The Employee Benefit Research Institute (EBRI) estimates that approximately one-third of workplace retirement balances are under $7,000 at any given time.

“If you contribute to a retirement account, it should still be there when you go looking for it,” said Romi Savova, CEO of PensionBee. “Millions of Americans have small 401(k)s sitting with old employers, and most have no idea that money can be moved into an account that slowly drains their savings. These accounts should be invested for the long term, like the 401(k)s they came from. The best protection is to find your old accounts and keep them under your control.”

The findings suggest opening fees as high as $100 are a key reason for early losses in Automatic Rollover IRAs. A $100 opening fee, plus a $5 monthly maintenance charge, adds up to $160 in the first year. On a $1,200 balance, that is 13% of the account gone before it can earn anything back.

Built to be temporary, many accounts stay for years

Automatic Rollover IRAs were designed as a short-term home for balances until former employees claim them. In practice, accounts remain for years:

• 87% of accounts remain after one year
• 75% of accounts remain after three years
• 52% of accounts remain after eight years

In the meantime, most accounts sit almost entirely in cash-like investments earning 0.5% to 2% interest a year, which may not be enough to keep up with the account’s fees. In contrast, a standard 401(k) can return a historical average of 5% to 8%.

While retirement accounts are expected to grow over time, many Automatic Rollover IRAs sustain significant losses. EBRI’s data suggests the longer balances linger, the more likely they are to lose a substantial portion of their original value.

Share of accounts that lost value, year one vs. year eight:

• Lost 25% or more: 4.6% in year one to 11.3% by year eight
• Lost 50% or more: 2.8% in year one to 8.2% by year eight
• Lost 75% or more: 1.8% in year one to 6.1% by year eight

Earlier research by PensionBee documented how this combination can deplete smaller accounts entirely to $0. Under one widely used provider’s published fees, a $1,000 account earning 1% would be charged down to $0 in about 29 years, less than the average working life of around 40 years.

Younger workers, who change jobs most often, are especially exposed. Most Automatic Rollover IRA owners are 44 or younger.

How to tell if your old 401(k) was moved

You may have money in an Automatic Rollover IRA if any of these apply to you:

• You left a job in the last 10 years without moving your 401(k).
• Your balance was under $7,000 when you left.
• You have changed your address or email since then.
• You got mail from an IRA provider you don’t recognize, or never heard anything at all.

To track down an old account, contact your former employer’s HR team or plan administrator. They chose the IRA provider and can tell you where your money went. The U.S. Department of Labor’s Retirement Savings Lost and Found database and your state’s unclaimed property office can also help. Once you find an account, you can move it into your current 401(k) or an IRA you choose.

Many savers never learn their money was moved into an Automatic Rollover IRA. Previous PensionBee research found only 35% of people with a left-behind 401(k) know it can be moved without their consent.

Annual automatic rollovers are projected to double from 1.1 million in 2022 to 2.2 million by 2030. By then, an estimated 13 million accounts holding $43 billion may sit in Automatic Rollover IRAs.

About the Research
The white paper, “How Automatic Rollover IRAs Can Wear Down Retirement Savings,” draws on account-level data provided by EBRI combined with PensionBee‘s proprietary analysis of market practices and account performance trajectories. All recommendations are those of PensionBee. EBRI was involved only in the analysis of the IRA data, not in the formulation of any recommendations.

For more information on the methodology or to read the white paper, please visit the link here.

About PensionBee

PensionBee (LON:PBEE; OTCQX:PBNYF) is a leading retirement savings provider, helping people easily consolidate, manage, and take control of their retirement savings. The company manages over $11 billion in assets and serves nearly 330,000 customers globally, with a focus on simplicity, transparency, and accessibility. PensionBee offers Traditional, Roth, SEP, and Automatic Rollover IRAs with ETF-backed portfolios. PensionBee is publicly traded on the London Stock Exchange (PBEE) with U.S. shares available on OTCQX (PBNYF).

Notes:
The information provided in this announcement, including any projections for investment returns and future performance, is for informational and educational purposes only and should not be considered investment advice. Past performance is not indicative of future results. All investments carry risk, including the potential loss of principal. PensionBee is not liable for any losses or damages arising from the use of this information. Projections and forecasts are based on assumptions and current market conditions, which are subject to change.

Media Contact:
Adela McVicar
Sr. PR Manager, PensionBee
adela.mcvicar@pensionbee.com

• Fenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, addressing a primary driver of long-term disability progression in multiple sclerosis (MS)
• Fenebrutinib FENhance 1 & 2 Phase III pooled data show a 55% reduction in annualised relapse rate (ARR) vs active comparator
• Following European Commission paediatric approval on 15 October, new Ocrevus OPERETTA 2 Phase III data show 90% of children aged 10–17 remained relapse-free over two years
• Featured in “Best of MSToronto2026”, Enspryng METEOROID Phase III data highlight significant attack reduction and improved functional recovery in MOGAD, an underserved autoimmune disease

Basel, 21 October 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new Phase III data for investigational fenebrutinib in multiple sclerosis (MS), demonstrating reduced markers of chronic brain inflammation as well as more comprehensive disease control versus active comparators.^1-3 These findings, alongside new Ocrevus® (ocrelizumab) and Enspryng® (satralizumab) data, will be featured across more than 40 abstracts at MSToronto2026 (10th ACTRIMS- ECTRIMS Meeting), held 21 to 23 October in Toronto. Highlights include a fenebrutinib late-breaking presentation and an Enspryng presentation in the “Best of MSToronto2026.⁴

“Addressing long-term disability progression to preserve people’s independence remains a critical challenge in neuroinflammatory diseases, and particularly in multiple sclerosis,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Our recent data indicate that fenebrutinib can inhibit disease activity inside and outside the central nervous system, underscoring its potential to transform care for people living with relapsing and primary progressive forms of multiple sclerosis.”

Fenebrutinib targets progressive biology inside the brain
New data from the pivotal trials in RMS (FENhance 1 and 2) and PPMS (FENtrepid) support the potential of fenebrutinib as the first and only high-efficacy oral medicine for both forms of MS.

• Reduction of chronic active lesions (Late-breaking oral #O137): In the first prospective demonstration of a therapeutic effect on chronic active lesions in MS Phase III clinical trials, data show fenebrutinib reduced the volume of slowly expanding lesions (SELs) by up to 30% (p<0.001) in RMS (over 96 weeks) and PPMS (over 120 weeks), along with a 62% (p=0.001) reduction in accumulation of paramagnetic rim lesions (PRLs) in RMS, versus active comparators. These findings demonstrate that fenebrutinib directly targets chronic neuroinflammation in the brain, a primary driver of disability progression in MS.¹
• Comprehensive disease control (Poster #P1434): In the pooled RMS trials, three quarters (75%) of fenebrutinib-treated patients showed no evidence of disease activity (NEDA-3) meaning zero relapses, zero MRI activity and zero worsening disability at nearly two years, a 70% reduction (p<0.001) versus the comparator. These results show fenebrutinib’s potential to suppress disease activity and delay progression.²
• Preserving brain volume and function (Oral #O089): Pooled RMS data show fenebrutinib reduced the annualised relapse rate (ARR) by 55% versus the comparator (p<0.001) over 96 weeks. In addition, fenebrutinib reduced annual total brain volume loss by 23% (p<0.001) and 12-week composite confirmed disability progression by 16% (p=0.04). These findings demonstrate fenebrutinib’s potential to control relapses, to slow brain tissue loss caused by neuronal cell death and to preserve function.³

Ocrevus provides consistent benefits across all age groups
New data show that Ocrevus provides significant and consistent efficacy across a broad MS patient population, from children 10 years of age to older adults.

• Two-year data and immune function in paediatric MS (3 posters on the Phase III OPERETTA 2 study): 90% of children with relapsing-remitting MS (RRMS) treated with Ocrevus, who were 10-17 years old at trial entry, remained free of relapses over two years (#P1439).⁵ Ocrevus selectively depleted target B cells with little to no effect on other immune cells (#P1407), while preserving pre-existing immunity to common childhood vaccines in 81–100% of patients (#P1415). The European Commission approved Ocrevus in this indication on 15 October, following FDA approval in May.^6,7
• Two-year data in patients >55 years old (Poster #P1426 on the Phase IIIb CONSONANCE study): 53% of participants over 55 years old treated with Ocrevus showed no disability progression after two years, similarly to younger participants (55%), showing Ocrevus maintains its effect on progression as people age.⁸
• Switching from other treatments to Ocrevus: Real-world data show progression was the leading reason for patients switching from ofatumumab to Ocrevus (ePoster #EP2733).⁹ A separate analysis of patients treated with Ocrevus or ofatumumab for one year show Ocrevus was associated with lower MRI lesion activity (Poster #P0305).¹⁰

Enspryng reduces risk of attack and is associated with improved recovery
Exploratory analyses of the pivotal METEOROID trial suggest that in addition to significantly lowering the risk of relapse (AAN 2026), Enspryng was associated with improved recovery and reduced disability progression, which is critical to prevent permanent damage to the optic nerves, spinal cord or brain in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). These findings reinforce Enspryng’s potential to become the first FDA-approved treatment for MOGAD, with a decision in the U.S. expected in January 2027.^4,11

• Relapse recovery (Oral #O035): Patients treated with Enspryng achieved numerically superior recovery at 12 weeks post relapse versus placebo (median change in Expanded Disability Status Scale [EDSS] of -2 vs -0.5). Overall function was stable (median 0) with Enspryng, compared to worsening (median 0.5) with placebo, as measured with the EDSS at the end of the double-blind period or first relapse.⁴ 

About fenebrutinib
Fenebrutinib is an investigational oral, central nervous system (CNS)-penetrant, reversible and non-covalent Bruton’s tyrosine kinase (BTK) inhibitor with an optimised pharmacokinetics (PK) profile. Fenebrutinib can act throughout the body and also cross the blood-brain barrier into the CNS to target chronic inflammation. It is uniquely designed to target relapsing and progressive biology by inhibiting cells in the immune system known as B cells and microglia. Targeting B cells helps control the acute inflammation that causes relapses, while targeting microglia inside the brain addresses the chronic damage that is thought to drive long-term disability progression.

While most current BTK inhibitors are covalent and irreversible, meaning they form a permanent chemical bond with the enzyme, fenebrutinib is non-covalent and reversible, meaning it binds and then eventually releases the enzyme.

About Ocrevus® (ocrelizumab)
Ocrevus is a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage. Ocrevus IV and Ocrevus subcutaneous (SC; marketed as Ocrevus Zunovo® [ocrelizumab hyaluronidase-ocsq] in the U.S.) are the only therapies approved for both RMS (including relapsing-remitting multiple sclerosis [RRMS] and active, secondary progressive multiple sclerosis [SPMS], as well as clinically isolated syndrome [CIS] in the U.S.) and primary progressive multiple sclerosis (PPMS). Both Ocrevus IV and SC are administered every six months. The initial IV dose is given as two 300 mg infusions two weeks apart with subsequent doses given as single 600 mg infusions. Ocrevus SC is given as a single 920 mg subcutaneous injection every six months.

About Enspryng® (satralizumab)
Enspryng, developed by Chugai, a member of the Roche Group, is a humanised monoclonal antibody that binds to both soluble and membrane-bound interleukin-6 receptors (IL-6R), thereby inhibiting IL-6 mediated signalling, a key pathway involved in inflammation. Enspryng incorporates Chugai’s proprietary antibody recycling technology, which enables pH-dependent binding to IL-6R and repeated engagement of the target, extending antibody circulation and supporting sustained inhibition of IL-6 mediated signalling.

Enspryng is the first and only IL-6R inhibitor treatment currently approved in approximately 90 countries for neuromyelitis optica spectrum disorder (NMOSD), including in the U.S. and E.U., with a well-established safety profile in over 16,000 patients. Enspryng was also recently approved for the treatment of thyroid eye disease (TED) in the U.S.

Roche is committed to developing Enspryng in additional neurological autoimmune and inflammatory diseases that may benefit from inhibition of IL-6 mediated signalling, including myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and autoimmune encephalitis (AIE).

About Roche in Neurology
Neurology is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new diagnostics and treatments that help improve the lives of people with chronic and potentially devastating diseases globally.

Roche is investigating more than a dozen medicines for neurological conditions, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and Duchenne muscular dystrophy. Roche Diagnostics has developed a broad range of approved and investigational tools, including digital and blood-based tests and cerebrospinal fluid (CSF) assays, aiming to more effectively detect, diagnose and monitor neurological conditions. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neurology today.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Oh J, et al. Fenebrutinib Shows a Therapeutic Effect on MS Progressive Biology: Outcomes on Paramagnetic Rim Lesions and Slowly Expanding Lesions in the Phase III FENhance I/II and FENtrepid Trials in Relapsing and Primary Progressive Multiple Sclerosis (#O137). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 23 October 2026; Toronto, Canada.
[2] Cerqueira JJFCA, et al. No Evidence of Disease Activity With Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results From the Phase III FENhance 1 and 2 Trials (#P1434). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 22 October 2026; Toronto, Canada.
[3] Sormani MP, et al. Efficacy of Fenebrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis: Pooled Analysis Results From the FENhance 1 and 2 Studies (#O089). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 21 October 2026; Toronto, Canada.
[4] Marignier R, et al. Severity and Recovery of Relapses in Patients with Relapsing MOGAD Treated with Satralizumab: Results from the Phase 3 METEOROID Study (#O035). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 22 October 2026; Toronto, Canada.
[5] Deiva K, et al. OPERETTA 2: Continued Follow-Up of the Efficacy and Safety Profile of Ocrelizumab in Pediatric Relapsing-Remitting MS (#P1439). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 22 October 2026; Toronto, Canada.
[6] Bar-Or A, et al. Impact of Ocrelizumab vs Fingolimod on Immune Function in Pediatric Patients With MS in the OPERETTA 2 Study (#P1407). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 22 October 2026; Toronto, Canada.
[7] Banwell B, et al. Vaccination and Disease-Modifying Therapies: Impact of Ocrelizumab vs Fingolimod on Preexisting Vaccine Seropositivity and Vaccine-Preventable Infections in Pediatric Patients With MS in OPERETTA 2 (#P1415). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 22 October 2026; Toronto, Canada.
[8] Butzkueven H, et al. Ocrelizumab Maintains Clinical and Safety Outcomes in Older Patients (>55 Years) with Progressive Multiple Sclerosis: 2-Year Results from the CONSONANCE Study (#P1426). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 22 October 2026; Toronto, Canada.
[9] Marriott J, et al. Switching Patients with Multiple Sclerosis from Ofatumumab to Ocrelizumab: A Real-World Study of Canadian Healthcare Professionals (#EP2733). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 21-23 October 2026; Toronto, Canada.
[10] Ziemssen T, et al. Brain Volume Loss and T2 Lesion Activity in RRMS: Real-World Longitudinal Comparison of Ocrelizumab vs. Ofatumumab (#P0305). Presented at: MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting; 21 October 2026; Toronto, Canada.
[11] Levy M, et al. Safety and Efficacy of Satralizumab in Patients with Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD): Results from the Phase 3 METEOROID Trial (PL5.006). Presented at: 78th Annual Meeting of the American Academy of Neurology (AAN) 2026; 21 April 2026; Chicago, IL, USA.

Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com

Tristan Schmitz Phone: +41 79 529 70 35	Lorena Corfas Phone: +41 79 568 24 95
Simon Goldsborough Phone: +44 797 32 72 915	Karsten Kleine Phone: +41 79 461 86 83
Kirti Pandey Phone: +41 79 398 38 53	Yvette Petillon Phone: +41 79 961 92 50
Irène Stephan Phone:  +41 79 377 83 75	Albert Thottiyil Phone: +41 79 775 66 12

Roche Investor Relations

Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

Attachment

• Media&Investor Release MSToronto2026 English

• Planned 300MW Badajoz campus provides foundation for European AI Cloud capacity; initial operations targeted for 2028
• IREN establishes IREN Europe, with Roberto Purcaro appointed as Executive Director for Europe, and the European board chaired by former Banco Santander CEO Ángel Corcóstegui
• Campus designed for compatibility with NVIDIA DSX AI Factory Platform; IREN to offer managed AI cloud services for customers with data residency and operational requirements

BERLIN, Oct. 21, 2026 (GLOBE NEWSWIRE) — At NVIDIA GTC Berlin, IREN (NASDAQ: IREN) today announced that it has established IREN Europe and secured the civil works license for its planned AI data center in Badajoz, Extremadura, Spain. The project is planned to deliver approximately 300MW of capacity, with initial operations targeted for 2028.

IREN plans to offer AI cloud services from Badajoz, including managed services, to customers seeking greater choice over where their AI workloads run and how their data and infrastructure are managed in Europe. The campus is part of IREN’s announced portfolio of more than 5GW of grid-connected power across North America, Europe and Asia-Pacific, positioning IREN to serve customers with different data residency requirements in each region.

“For customers in Europe, sovereign AI starts with two questions: where their data sits and who’s running the infrastructure,” said Daniel Roberts, Co-Founder and Co-CEO of IREN. “That’s what IREN Europe is for: our own sites, run by our own people, with a board that’s accountable in Europe. Ángel and Roberto have spent their careers building and financing infrastructure globally and in Iberia, and Badajoz is the first project in Europe.”

The Badajoz campus

At Badajoz, IREN has secured grid-connected power and the civil works license for its planned 300MW campus. IREN continues to be in close consultation with local, regional and national authorities as the project advances. The campus is designed around closed-loop liquid cooling, which requires minimal water for cooling. It’s also designed for compatibility with NVIDIA DSX AI Factory Platform.

IREN establishes European leadership

IREN has appointed Ángel Corcóstegui as Chair of the newly established board of directors of IREN Europe, the holding company for its European operations. Roberto Purcaro has been appointed Executive Director for Europe and joins the board.

IREN entered Europe in June 2026 with the acquisition of Nostrum Group, a Spain-based data center developer, and its team of more than 60, led by Gabriel Nebreda, Chief Executive Officer of IREN Spain.

Corcóstegui served as First Vice Chairman and Chief Executive Officer of Banco Santander, where he led the integration of Banco Santander and Banco Central Hispano. He co-founded Magnum Capital, a private equity firm focused on Spain and Portugal. His infrastructure and energy experience includes chairing the engineering group Eptisa, Magnum Capital’s control of the Portuguese wind operator Iberwind from 2008 to 2015, and a current seat as independent director of Moeve.

Purcaro brings more than 25 years of international experience in infrastructure, energy transition and digital infrastructure. Most recently, as Global Head of Complex Opportunities and Head of Italy at Macquarie Capital, he led the structuring of large-scale transactions involving multinational corporations, sovereign institutions and global investors.

“Spain has exceptional conditions to become a European hub for AI digital infrastructure, thanks to its excellent connectivity and abundant, competitive renewable energy,” said Corcóstegui. “It is an honor to chair IREN Europe and I look forward to helping execute our growth plans.”

“Badajoz is where IREN Europe begins,” said Purcaro. “IREN develops its own sites and operates them directly, and that’s how we’ll work in Europe. Our focus from here is the campus and the customers who’ll use it.”

Managed AI cloud services in Europe

Following the completion of its acquisition of Mirantis, IREN’s software capabilities, including k0rdent AI, can provision and manage AI infrastructure. These capabilities include workload isolation and operational controls that can help customers address data residency, security and governance requirements. k0rdent AI also integrates NVIDIA technologies, including NVIDIA Infra Controller (NICo) and NVIDIA Run:ai, into its unified platform. IREN intends to offer these capabilities alongside its European capacity as it comes online.

About IREN

IREN is a vertically integrated AI Cloud platform, delivering data centers, compute and software for AI training and inference. IREN’s platform is underpinned by its expansive portfolio of land and grid-connected power in renewable-rich regions across North America, Europe and Asia-Pacific.

Contacts

Investors
ir@iren.com

Media
media@iren.com

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or IREN’s future financial or operating performance. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies, expectations as to development and construction timelines, anticipated benefits of new board and executive appointments, expansion into new geographies, receipt of government permits and approvals, grid connections, availability of financing, and other trends we expect to affect our business. Forward-looking statements often include words such as “anticipate,” “believe,” “may,” “can,” “should,” “could,” “might,” “plan,” “possible,” “project,” “strive,” “budget,” “forecast,” “expect,” “intend,” “target,” “will,” “estimate,” “predict,” “potential,” “continue,” “scheduled” “aim,” or other similar terminology. Forward-looking statements may also be made, verbally or in writing, by members of our Board or management team in connection with this press release.

These forward-looking statements are based on management’s current expectations, plans, estimates, assumptions, and beliefs. These statements are neither promises nor guarantees, but involve and are subject to known and unknown risks, uncertainties and other important factors that may cause IREN’s actual results, performance or achievements to differ materially from any future results performance or achievements expressed or implied by the forward-looking statements, including IREN’s ability to successfully execute on its growth strategies and operating plans, including to commence operations of the Badajoz campus in 2028, deploy up to 5GW of NVIDIA DSX-aligned AI infrastructure and deliver AI cloud services in the European region, achieve its targeted annualized AI Cloud Services revenue, continue to develop its existing data center sites, design and deploy direct-to-chip liquid and air cooling systems, provide software, and operate and expand its AI Cloud Services business, along with other important factors discussed under the caption “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in IREN’s Annual Report on Form 10-K, filed with Securities and Exchange Commission (the “SEC”) on August 27, 2026 and IREN’s Quarterly Reports on Form 10-Q, filed with the SEC from time to time. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any forward-looking statement included in this press release speaks only as of the date of such statement. Except as required by law, IREN disclaims any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise.

ST. LOUIS, Oct. 21, 2026 (GLOBE NEWSWIRE) — Advantage Solutions Inc. (NASDAQ: ADV), announced today that it will release financial results for the third quarter at 7 a.m. EST on November 4, 2026, followed by a conference call at 8:30 a.m. EST on the same day.

The conference call can be accessed live by dialing 1-833-461-5787 for U.S. callers or 1-585-542-9983 for international callers. The conference ID is 693618856. Interested investors and other parties may also listen to a simultaneous conference call webcast by logging onto the Investor Relations section of the Advantage Solutions website at ir.youradv.com.

A replay of the webcast will be available for a limited time on the Investor Relations section of the Advantage Solutions website at ir.youradv.com.

About Advantage Solutions

Advantage Solutions is the leading omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers. With its data- and technology-powered services, Advantage leverages its unparalleled insights, expertise and scale to help brands and retailers of all sizes generate demand and get products into the hands of consumers, wherever they shop. Whether it’s creating meaningful moments and experiences in-store and online, optimizing assortment and merchandising, or accelerating e-commerce and digital capabilities, Advantage is the trusted partner that keeps commerce and life moving. Advantage has offices throughout North America and strategic investments and owned operations in select international markets. For more information, please visit YourADV.com.

Investor Contacts:
investorrelations@youradv.com

Media Contacts:
press@youradv.com

• Hebei Shoulang New Energy Technology Co., Ltd. (“Hebei Shoulang”) in Tangshan, Hebei Province, China, has achieved ISCC EU Recycled Carbon Fuel (RCF) producer certification
• ISCC EU certification verifies compliance with the sustainability criteria and GHG savings methodology implemented under the EU’s Renewable Energy Directive (RED III) and is recognized by the European Commission. It is also approved by the UK’s Department for Transport to demonstrate compliance with the Renewable Transport Fuel Obligation (RTFO) and the UK SAF Mandate
• Certificate was issued under the ISCC EU scheme, following an audit by SCS Global Services and its China-based affiliate, Beijing Green Forest Certification

SKOKIE, Ill., Oct. 21, 2026 (GLOBE NEWSWIRE) — LanzaTech Global, Inc. (NASDAQ: LNZA) (“LanzaTech”) today announced that Hebei Shoulang, located in Tangshan, Hebei Province, China, has been certified under the International Sustainability and Carbon Certification (ISCC) EU scheme as a Recycled Carbon Fuel (RCF) producer.

The ISCC EU certification standard is recognized by the European Commission. It complies with the sustainability criteria laid down in the Renewable Energy Directive (2018/2001/EU), which promotes the use of renewable energy sources.

Hebei Shoulang is a wholly-owned subsidiary of Beijing Shougang LanzaTech Technology Co., Ltd., (“SGLT”, 02553.HK). The facility uses patented gas fermentation technology licensed from LanzaTech to convert waste gases from steel production into ethanol. Certification enables certified and compliant volumes of the facility’s ethanol to be marketed as recycled carbon fuel for direct use in European Union marine and road markets, as well as for aviation fuel markets in the European Union and United Kingdom, subject to any additional regulatory requirements in those markets.

“This is a significant milestone for SGLT and for the Hebei Shoulang facility,” said Qingkun Song, Deputy General Manager of SGLT. “Achieving ISCC EU certification for recycled carbon fuel shows that carbon recycling is not only technically proven, but commercially relevant in regulated fuel markets. We are proud to help establish this new category and to support growing demand for certified lower-carbon fuels across Europe and beyond.”

Under RED III, EU Member States require fuel suppliers to incorporate increasing shares of renewable fuels to meet national transport decarbonization targets, and may allow recycled carbon fuels to count toward them. ISCC EU certification provides the verified sustainability, GHG emission savings calculations and chain-of-custody documentation obligated parties need to count certified volumes of ethanol, including from Hebei Shoulang, toward these targets, where national rules allow.

Meo Carbon Solutions, a sustainability consultancy specializing in greenhouse gas accounting, regulatory advice, and certification pathways for sustainable fuels, supported LanzaTech and Hebei Shoulang through the process. LanzaTech also worked with Brookfield to address renewable power requirements for the facility, a complex element of the pathway that is expected to inform future recycled carbon fuel certifications.

“Achieving ISCC EU certification for recycled carbon fuel at Hebei Shoulang is a critical step in opening regulated European fuel markets to our CarbonSmart ethanol,” said Dr. Jennifer Holmgren, CEO and Board Chair of LanzaTech. “This is not just another certificate; it creates a near-term pathway to monetize recycled carbon in EU marine and road markets, while positioning us for aviation opportunities in the EU and UK. In mandated markets where verified carbon intensity carries real value, certification is what turns customer interest into revenue opportunity and accelerates our path to profitability.”

Additional Supporting Quotes:

Quote from Dario Formenti, ISCC Senior Manager & Technical Lead for Aviation & Maritime, ISCC System GmbH:
“For ISCC, it has been a pleasure to continue working with LanzaTech and to see its facility in China achieve ISCC EU certification for Recycled Carbon Fuels, supporting the broader development of the renewable fuels ecosystem. As a leading sustainability certification scheme, ISCC supports organizations globally to build credible, sustainable supply chains through rigorous certification, including for innovative feedstocks and production pathways. This allows emerging technologies and fuels to demonstrate compliance with sustainability requirements and access regulated markets.”

Quote from Don Scott, ISCC Program Director, SCS Global Services:
“This certification proves that recycled carbon fuels can meet the same rigorous sustainability standards that govern the rest of the renewable fuel market. Our audit confirmed that Hebei Shoulang’s chain of custody and greenhouse gas accounting meet the ISCC EU scheme’s requirements. This achievement shows that facilities converting industrial waste gas into usable fuel can meet the standards that regulated European markets demand.”

Quote from Dr. Carola Krevert, Senior Project Manager & Team Lead New Market Certification, Meo Carbon Solutions GmbH:
“The successful certification of Hebei Shoulang demonstrates the value of combining deep local market expertise with strong regulatory and certification knowledge. LanzaTech’s understanding of the Chinese market and innovative technology, together with Meo Carbon Solutions’ expertise in certification requirements, including the EU Renewable Energy Directive (RED) framework and ISCC EU scheme, helped support a complex certification process. We are proud to have contributed to this important milestone and look forward to seeing recycled carbon fuels play an increasing role in the transition to more sustainable transport fuels.”

About LanzaTech

LanzaTech (NASDAQ: LNZA) is a leader in carbon management, using its proprietary gas-fermentation platform to transform waste carbon into valuable products. Through global partnerships, LanzaTech enables the production of feedstocks for high-value markets including SAF and chemicals. Headquartered in the U.S., the company provides technology and commercial pathways that strengthen industrial resilience and unlock new economic value from carbon.

About ISCC

Founded in 2010 through a multi-stakeholder initiative, the International Sustainability and Carbon Certification (ISCC) is a globally applicable and leading certification system designed to enhance traceable, sustainable, deforestation-free, and climate-friendly supply chains.

Public Relations/Media Contact:
freya@lanzatech.com